Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (injection) Clear all
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

NCT00567086
View directory record Official record
Conditions
Migraine
Interventions
TEZAMPANEL
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2007 · Synced Sep 5, 2026, 12:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

NCT02421367
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 49 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

NCT00419263
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 150 mg, Peramivir 300 mg, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
58
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Results available

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00443430
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 5, 2026, 12:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

NCT02020616
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3053102, Exenatide ER, Placebo, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Orange, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

NCT04659863
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

NCT04570384
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
L-Citrulline, Placebo
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752
View directory record Official record
Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
CBP-201, placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 5, 2026, 12:49 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Poly-L-lactic Acid for Skin Quality

NCT02003833
View directory record Official record
Conditions
Skin Aging
Interventions
Poly-L-lactic acid, Placebo comparator
Device
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Carmel, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 5, 2026, 12:49 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Placebo, Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
17
States / cities
Mesa, Arizona • Los Angeles, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 5, 2026, 12:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

NCT03559517
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 5, 2026, 12:49 AM EDT
Completed Phase 3 Interventional

Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

NCT02959476
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ropivacaine, Placebos
Drug
Lead sponsor
BioQ Pharma, Inc.
Industry
Eligibility
Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Sheffield, Alabama • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 5, 2026, 12:49 AM EDT